Possible miliary tuberculosis during adalimumab therapy with negative gamma-IFN release assays.
Endean
A L
AL
Barry
S M
SM
Young-Min
S A
SA
D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects*; D005188:False Negative Reactions; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis*; D009894:Opportunistic Infections / Q000139:chemically induced*; D013167:Spondylitis, Ankylosing / Q000188:drug therapy; D014391:Tuberculosis, Miliary / Q000139:chemically induced*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007371:Interferon-gamma; D000068879:Adalimumab